← Eichor
Condition: Unresectable Metastatic Melanoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Unresectable Metastatic Melanoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Mela
Phase 1 · 4 location(s) · Alpha-9 Oncology USA Inc. · NCT07076550MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
Phase 1/Phase 2 · 13 location(s) · Perspective Therapeutics · NCT05655312Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectabl
Phase N/A · 1 location(s) · John Kirkwood · NCT07223411Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma
Phase 1/Phase 2 · 1 location(s) · Shanghai JMT-Bio Inc. · NCT07280832A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectabl
Phase 2 · 31 location(s) · Innovent Biologics (Suzhou) Co. Ltd. · NCT06797297Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With P
Phase 3 · 19 location(s) · mAbxience Research S.L. · NCT07221734Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial
Phase 2 · 2 location(s) · Emory University · NCT07155317Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Neg
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT05098210Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07627698A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melan
Phase 3 · 110 location(s) · Regeneron Pharmaceuticals · NCT06246916A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works
Phase 1/Phase 2 · 11 location(s) · Regeneron Pharmaceuticals · NCT06413680Predictive Factors of Complete Response to Immunotherapy in Metastatic Melanoma: a Single-center Retrospective Study Bet
Phase N/A · 1 location(s) · University Hospital, Strasbourg, France · NCT07302607Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients
Phase N/A · 1 location(s) · University of Wisconsin, Madison · NCT06199713A Study of ST-1898 for Unresectable or Metastatic Melanoma
Phase 1/Phase 2 · 1 location(s) · Beijing Scitech-Mq Pharmaceuticals Limited · NCT06359860Follow-up of a National Cohort of Melanoma Resectable Stage II, Stage III or IV Patients or Unresectable Primary
Phase N/A · 27 location(s) · Assistance Publique - Hôpitaux de Paris · NCT02828202Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access an
Phase 2 · 1 location(s) · Mayo Clinic · NCT06265285Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Loc
Phase 1/Phase 2 · 18 location(s) · Aulos Bioscience, Inc. · NCT05267626BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or S
Phase 2 · 225 location(s) · National Cancer Institute (NCI) · NCT05136196ACTengine® IMA203 Combined With mRNA-4203
Phase 1 · 4 location(s) · Immatics US, Inc. · NCT06946225A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
Phase 1/Phase 2 · 5 location(s) · Iovance Biotherapeutics, Inc. · NCT06940739AMT-253 in Patients With Advanced Solid Tumours
Phase 1/Phase 2 · 1 location(s) · Multitude Therapeutics Inc. · NCT06209580SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutan
Phase 3 · 66 location(s) · Immatics US, Inc. · NCT06743126GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
Phase 1/Phase 2 · 4 location(s) · GeneMedicine Co., Ltd. · NCT06265025Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unr
Phase 2 · 4 location(s) · NYU Langone Health · NCT05428007Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT05269381A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants W
Phase 1/Phase 2 · 32 location(s) · Marengo Therapeutics, Inc. · NCT05592626A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Met
Phase 1/Phase 2 · 11 location(s) · Iovance Biotherapeutics, Inc. · NCT05361174A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma
Phase 1/Phase 2 · 1 location(s) · Zhuhai Yufan Biotechnologies Co., Ltd · NCT06727630High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT05053555Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metasta
Phase 1/Phase 2 · 26 location(s) · National Cancer Institute (NCI) · NCT05896839
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.